Breakthrough pain of caner
Conditions
Interventions
Butorphanol nasal spray group (Group B):Butorphanol tartrate nasal spray, 1 to 2 sprairies when breakthrough pain happens
Morphine injection group (M group):Morphine injection injection (when outbreak pain occurs)
Sponsors
Liaocheng People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Cancer patients aged 18-80 years. 2. Patients with cancer pain that is moderate to severe pain based on an NRS score of >3, as assessed by screening, who require titration of extended-release analgesic medication. 3. Patients presenting with outbreak pain with an NRS score >3 and requiring analgesic medication for relief. 4. 18 kg/m2 <= BMI <= 30 kg/m2; male and female are not limited. 5. Clearly understand and voluntarily participate in the study, and have their informed consent signed by themselves.
Exclusion criteria
Exclusion criteria: 1. Patients with contraindications in the instructions for Nojan's Butorphanol Tartrate Nasal Spray. 2. Patients with combined use of hormones, non-steroidal drugs, antidepressant and anticonvulsant drugs for analgesia. 3. Major organ failure, such as decompensated cardiac, pulmonary, hepatic and renal failure. 4. Consciousness impairment, cognitive dysfunction or combination of other psychiatric disorders. 5. Women during pregnancy or lactation. 6. Patients with elevated intracranial pressure and brain injury. 7. Patients with myocardial infarction, cardiac dysfunction, coronary artery insufficiency. 8. Patients with alcoholism, hypertension. 9. Paired with a drug clinical trial as a subject within the last 3 months. 10. Other conditions that the investigator considers inappropriate for participation in this trial. 11. Patients with oral or nasal mucosal injury (e.g. injury after radiotherapy for nasopharyngeal cancer).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pain score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Survival quality score;Satisfaction evaluation;Remedial drug utilization; | — |
Countries
China
Contacts
Public ContactLi Mingjun
Outcome results
None listed